10.11.2016 • NewsDede WillamsProbeInvestigation

EU Restarts Dow-DuPont Merger Probe

(c) Pack-Shot/Shutterstock
(c) Pack-Shot/Shutterstock

After receiving the key data previously requested from Dow and DuPont, the European Commission has restarted its in-depth investigation of the $130 billion merger between the two US chemical giants. The EU regulatory authority said last week it had stopped the clock on the probe in October – for a second time – after the companies failed to submit crucial information.

A spokesman for the Commission said in an email to news agencies that it has set 28 February 2017 as the new date to complete the investigation. In the past it said it was concerned that the merger could reduce competition for crop protection and seeds as well as certain petrochemicals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.